Active — Not RecruitingPhase 2

ZN-c3 + Gemcitabine in Pancreatic Cancer

United States12 participantsStarted 2023-11-16

Plain-language summary

This study is being done to test the safety and effectiveness of combining ZN-c3 and Gemcitabine in participants with pancreatic cancer. The names of the study drugs involved in this study are: * ZN-c3 (a small molecule inhibitor of the WEE1 tyrosine kinase) * Gemcitabine (a nucleoside metabolic inhibitor)

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓-Evidence of non-childbearing status, defined as below:

What they're measuring

6-month Progression-Free Survival (PFS) Rate

Timeframe: 18 months

Trial details

NCT IDNCT06015659

SponsorBrandon Huffman, MD

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2025-08-06

View on ClinicalTrials.gov More Advanced Pancreatic Adenocarcinoma trials